Novavax to Participate in Fireside Chat at Goldman Sachs Virtual Conference

Rhea-AI Summary

Novavax (Nasdaq: NVAX), a biotechnology firm, will take part in a fireside chat at the Goldman Sachs virtual conference on April 13, 2021, from 2:30 to 3:20 p.m. ET. The discussion will focus on Novavax's COVID-19 vaccine candidate, NVX-CoV2373, and its implications for the current vaccine landscape. Vivek Shinde, M.D., M.P.H., Vice President of Clinical Development, will represent the company. This event is exclusive to Goldman Sachs clients, highlighting Novavax's ongoing efforts in developing innovative vaccines against serious infectious diseases.

GAITHERSBURG, Md., April 8, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in a fireside chat during the Goldman Sachs Recovery Inoculated: The Current Outlook for COVID-19 Vaccines, Treatments, Testing and the Economy virtual conference. Novavax' COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Fireside chat details:
Date:	Tuesday, April 13, 2021
Time:	2:30 – 3:20 p.m. Eastern Time (ET)
Panel title:	COVID-19 Vaccines – Staying Ahead of the Curve
Novavax participant:	Vivek Shinde, M.D., M.P.H., Vice President, Clinical Development
	This event is open to Goldman Sachs clients.

About Novavax

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:
Investors
Novavax, Inc.
Erika Schultz | 240-268-2022
ir@novavax.com

Solebury Trout
Jennifer Porcelli | 646-378-2962
jporcelli@soleburytrout.com

Media
Laura Keenan | 410-419-5755
Amy Speak | 617-420-2461
media@novavax.com

 

View original content:http://www.prnewswire.com/news-releases/novavax-to-participate-in-fireside-chat-at-goldman-sachs-virtual-conference-301265038.html

SOURCE Novavax, Inc.

FAQ

What is the date and time of Novavax's fireside chat at the Goldman Sachs conference?

The fireside chat will take place on April 13, 2021, from 2:30 to 3:20 p.m. ET.

Who will represent Novavax during the Goldman Sachs virtual conference?

Vivek Shinde, M.D., M.P.H., Vice President of Clinical Development, will represent Novavax.

What is the focus of the fireside chat involving Novavax?

The focus will be on Novavax's COVID-19 vaccine candidate, NVX-CoV2373.

Is the Goldman Sachs conference open to the public?

No, the event is open only to Goldman Sachs clients.

What type of company is Novavax?

Novavax is a biotechnology company developing vaccines for serious infectious diseases.